A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma.
Phase of Trial: Phase III
Latest Information Update: 18 Aug 2017
At a glance
- Drugs Lenvatinib (Primary) ; Everolimus; Pembrolizumab; Sunitinib
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms CLEAR
- Sponsors Eisai Inc
- 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 18 May 2017 Data from this trial will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) 2017, according to an Eisai Inc media release.
- 28 Sep 2016 Status changed from not yet recruiting to recruiting.